Life Sciences Archive » February, 2023

Life Sciences - February, 2023

311 articles

• Buyers Don't Qualify As Class In Lamictal Antitrust Case
• J&J Judge Rejects 'Whining' MDL Objection, Attys Get $2.5M
• Vidal Wants To Hear More About PTAB's Ruling On Pig Vax IP
• Abbott Wants 26 People Removed From Infant Formula MDL
• Families Blast 'Dehumanizing' Stance As Opioid Trial Closes
• Unilever Can't Nix TRESemme Shampoo User's Hair Loss Suit
• Bayer Must Face False Ad Suit Over 'Natural' Vitamins
• 3rd Circ. Preview: March Roars In With Workplace Disputes
• 2 Takeaways From 3rd Circ.'s J&J Bankruptcy Ruling
• DOJ Wins Kickback Verdict Threatening $485M Liability
• Roe's Demise Revives Texas Suit Over Abortion Services Funding
• FDA Cracks Down On Import Of Tranquilizer Linked To Deaths
• Venable Adds 2 JAG Medical Research Attys To FDA Group
• Life Sciences Group Of The Year: Cooley
• Insys Founder Says Prison Release Could Be 'Life-Saving'
• Chipmakers Can Start Applying For US Subsidies
• Drugmakers To Face Price-Fixing Claims From State AGs
• USTR Urged To Let 4 Countries Bypass Vertex's Trikafta IP
• Norfolk Southern To Allow More Exam Time At Derailment Site
• Ohio, US EPAs Sued Over 'Staged Farce' In Train Derailment
• FTC Pushes To Hold Shkreli In Contempt
• Drug Distributors Not The Cause Of Opioid Harm, Jury Told
• Dow Judge Tells Modesto: Take $16M Or New Punitives Trial
• Generics Makers Settle Liver Drug Patent Fight On Eve Of Trial
• Release Opt Out Trips Up Tricida Ch. 11 Disclosure Approval
• 7th Circ. Backs Humana's ADA Win Over Anxious Worker
• Catching Up With Delaware's Chancery Court
• Steps Lawyers Can Take Following Involuntary Terminations
• Pillsbury IP Litigator Joins Husch Blackwell's DC Office
• Life Sciences Group Of The Year: Latham
• Justices Won't Hear Pharmacist's Appeal In Deadly Outbreak
• 'Crafty' Defense Attys Bombarded In Supreme Court FCA Fight
• Elizabeth Holmes Cites Newborn In Ripping Flight Risk Claim
• Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers
• A Dozen Dem AGs Sue Over FDA's Abortion Drug Regulations
• Feds Want All $25M Of Insys Founder's Money For Restitution
• ITC Gets An Earful On Impact Of Possible Apple Watch Ban
• BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says
• FDA Plans Slew Of New Tobacco Program Efforts
• Monster Wants $167M Added To $293M VPX False Ad Verdict
• COVID Testing Firm To Seek Ch. 11 Bids By Early April
• Fed. Circ. Won't Let Jazz Keep System Patent In Orange Book
• High Court Ax Of Atty-Client Privilege Case Deepens Split
• Genus Claims Questions After Justices Deny Juno Rehearing
• Former New Mexico AG Counsel Joins Nachawati Law
• Akorn Files For Ch. 7 Liquidation With Over $100M Debt
• AthenaHealth Fights Whistleblower's Atty Fee Top-Up Request
• Late Filing Gets Westco Chemicals ERISA Suit Tossed
• Life Sciences Group Of The Year: Dechert
• UK Litigation Roundup: Here's What You Missed In London
• Ex-Pharma CEO Can't Undo Landmark Opioid Conviction
• End-Payors Ink $30M Novartis Exforge Deal
• Immunomedics' $40M Deal Over Data Scandal Gets Initial OK
• 6th Circ. Won't Revive Dow Corning Implant Settlement Claims
• Cannabis And Psychedelics Roundup: N.H. Eyes Legalization
• Abortion Pill Fate Hangs On Conservative Judge, 'Zombie' Law
• Warren Asks Feds To Review New Keytruda Patent Requests
• A Method To Measure Pay-For-Delay Drugs' Financial Impact
• Saying J&J Rival Shows 'No Respect,' Judge Issues Sales Ban
• Pharma Exec Traded On Kodak COVID Loan Info, Feds Say
• Ousted Kidney Test Founder Sues Startup Over Legal Fees
• 2 Firms Steer Biotech Firm's $425M Merger With US Rival
• High Court's FCA Showdown Is Already Shaping DOJ Probes
• COVID Test Maker Lucira Health Files For Ch. 11 Protection
• Atty Pushes Back After DOJ Says DEA Not An Agency
• Chamber Of Commerce Says Patent Policy 'Getting Stormy'
• Worker Must Pay For 'Egregious' Claim, Eli Lilly Says
• FDA Wants Plant-Based 'Milk' To Specify Nutrition Differences
• Ex-Judges Slam Panel Swap That Sunk Novartis Patent Win
• End Payors Latest To Drop Bankruptcy-Blocked Par Claims
• Health Orgs Tell 6th Circ. $650M Opioid Verdict Must Stand
• 3rd Circ. Asked To Look At New Precedent In Class Cert. Fight
• In First, FDA Fines E-Cig Cos. Over Unauthorized Products
• Circuit Split Complicates US Discovery In Foreign Tribunals
• Anthem Can't Ditch JetBlue, Alaska Airlines' Price Fixing Suits
• AbbVie, J&J Units Say Del. Judge's Rebukes Bolster Fee Bid
• 8 BigLaw Firms Sign On To New Abortion Defense Initiative
• 3 Job Satisfaction Questions For Partners Considering Moves
• State AGs May Put Investors On The Hook For Co. Bad Acts
• Hidden Costs Of FCA, Anti-Kickback Claims For Public Cos.
• Pa. Justices OK J&J Unit's $2.1M Tax Refund In Sourcing Fight
• Outcome Ex-Growth Chief Says Bad Business Was 'Pervasive'
• Ex-GE Lighting Cos. Owe $2M For Infringing Patent, Jury Says
• White House Won't Veto Potential ITC Apple Watch Ban
• US Chamber, Legal Groups Favor J&J Talc Ch. 11 Rehearing
• Gilead, Janssen And Teva Face HIV Drug Antitrust Trial In May
• Breaking IP Barriers With Banner Witcoff's Mercedes Meyer
• Justices Let SG Join Amgen Case, But Not Chemistry Group
• 50 Cent Settles Penile Enhancement Ad Suit With Publication
• Sorrento Cleared For Ch. 11 Loan Over Nant Entity Objection
• Anika Therapeutics Spars With Caligan Over Corporate Future
• State, Federal Disconnect Sows Confusion For CBD Industry
• French Court Nixes €444M Dominance Fine For Drug Cos.
• Renibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale
• Senate Judiciary Asked To Hold Hearings On 6 Mergers
• Robitussin 'Naturals' Cough Syrup Mislabeled, Suit Says
• 4 Exercises To Quickly Build Trust On Legal Teams
• High Court Won't Review $302M J&J Fine Appeal
• Feds Say Insys Founder's Health Doesn't Merit Early Release
• Fed. Circ. Resurrects Bard's Medical Injection Patents
• Lengthy Delay Dooms LabMD Suit, FTC Attys Tell DC Circ.
• Walmart Rejects Opioid Liability Over 'Unwitting' Pharmacists
• Vegan Dairy Co. Miyoko's Says Namesake Founder Stole IP
• 6th Circ. OKs Preliminary Injunction In Implant Co.'s Suit
• Judge Unwilling To Find Apple Stole Masimo Trade Secrets
• Balwani Fights 13-Year Sentence, $900M Restitution
• Attys Seek Out Of Cancer Patient's Monsanto Civil Rights Suit
• Catching Up With Delaware's Chancery Court
• NJ Justices Expand Factors For Drug Expert Testimony
• DNA Testing Co. Agrees To Beef Up Security After Data Breach
• DEA Erred In Rejecting Psilocybin Therapy, 9th Circ. Hears
• FCA Ruling 'Turned Law On Its Head,' Justices Hear
• 2nd Circ. Tosses Animal Rights FOIA Claim Against USDA
• Illicit Cannabis Is The Problem, Not State-Legal Markets
• Pharma, Consumer Advocates Clash Over FDA-USPTO Collab
• WDTX Judge Won't Send Ravgen Patent Suit Back To Albright
• TTAB Won't Let Diagnostic Co. Register 'NF-Light' TM
• 'Noisy Exit' Hits FTC At Crucial Moment
• Mitsubishi Touts $940M Arbitration Win Over Gilenya Royalties
• Sen. Grassley Plans FCA Amendments Amid 'Absurd' Rulings
• Hearing Aid Co. Eargo Beats Investor Suit Over DOJ Probe
• 8 Steps To Improve The Perception Of In-House Legal Counsel
• Teacher Urges 3rd Circ. To Renew Steroid Whistleblower Suit
• How High Court Amgen Case Could Alter Patent Enablement
• Life Science Investor To Spend €140M On Stock Buyback
• In 3rd Reversal, PTAB Will Eye Seagen Patent In $42M Case
• 3rd Circ. Upholds Dismissal Of Benicar Atty Fee Award Suit
• Flint Questioned On Funding For Residents' Info Requests
• Biotage Will Acquire Astrea Bio Business In $190M Stock Deal
• Bulk Of Human Milk Maker's TM Suit Survives Dismissal Bid
• 'Egregious' Opioid Sales Support $650M Verdict, 6th Circ. Told
• Red Cross Hit With Antitrust Suit For Platelet Treatment Tying
• These Firms Are Pulling In The Most Patent Litigation Work
• Trade Show Demo Sinks Gynecological Patent At Fed. Circ.
• Procedure Rule 7.1 Can Simplify Litigators' Diversity Analysis
• Firms Ask Del. Justices To Undo Fee Bid Denial In Vax Biz Suit
• Glaser Weil, Kirkland Lead $1.36B Sale Of Wyatt Technology
• Patent Suits Mostly Stayed Level In 2022, Yet Appeals Fell
• Moderna Is Wrong Target Of COVID Vax IP Claims, Feds Say
• Medtronic Hogs Surgical Market With Unfair Deals, Rival Says
• Jazz Argues Drug Patent Should Stay In Orange Book
• More Needed On Reproductive Rights, Senate Dems Tell Biden
• Philips Notches X-Ray IP Win After Defendant Goes Silent
• Opioids More Addictive Than Cocaine, Ga. Jury Told
• J&J Talc Unit Seeks 3rd Circ. Rehearing On Ch. 11 Dismissal
• FDA Says Legionnaires' Disease Found On Cruise Ship
• How Companies Could Define 'Social' In ESG Metrics
• DC Hospital Inks Deal To End Suit Over Water Shut-Off, COVID
• LabCorp Fends Off Class Cert., Second Billing Suit In NC
• Ga. Doc Tells 11th Circ. Roundup Claims Not Barred
• Forian Sells Cannabis Software Biz To Alleaves For $30M Cash
• CBD Buyers, Maker Fight Over Stay In Mislabeling Suit
• Biotech Co. Sued In Delaware Over 'Excessive' Director Pay
• 3rd Circ. Ruling Limits Add-On Money Laundering Charges
• FTC's GoodRx Action Highlights Risks For Digital Health Cos.
• Republican FTC Member Wilson Resigning Over Khan Policy
• 'Wake-Up Call': FCA Attys Seek Answers As Fraud Fight Falters
• Feds, Nobel Prize Winner Back Sanofi At High Court IP Fight
• Napa Valley Hilton Sued Over Legionnaires' Disease Outbreak
• Court Told Not To Toss Regeneron's Amgen Bundling Suit
• Azurity Loses Hypertension Drug Patent Trial Against Alkem
• Alcon Inc. To Pay $199 Million To Settle J&J Laser IP Dispute
• What To Expect From The House Select Committee On China
• FTC, States Defend Pesticide Antitrust Suit
• What High Court Case Could Mean For Gene Therapy Patents
• Cos. Sued Over Tainted Eye Drops Linked To Infection
• DEA Says 2 Lab-Derived Cannabis Compounds Are Schedule I
• Durbin Wants Life Science Cos.' Interlocking Boards Reviewed
• J&J Ch. 11 Ruling Highlights 'Texas Two-Step' Skepticism
• LabMD Sues Nonprofit, Dinsmore Over FTC Enforcement Case
• Ex-Theranos Exec Balwani Fights Feds' $900M Restitution Bid
• Fed. Circ. Remains Sour On Dartmouth's Milk Vitamin Patent
• 2 Firms Guide Fashion Distributor's $707M SPAC Merger
• Investor In Genomic Test Co. SPAC Sues Its Board In Del.
• Texas' Medical Cannabis Program May Soon Be Sittin' Pretty
• Merck, Glenmark Must Face Zetia Antitrust MDL At April Trial
• Catching Up With Delaware's Chancery Court
• Sorrento Therapeutics Hits Ch. 11 With Over $100M In Debt
• Roche Rips Bank's Counterclaims In $87M Test Strip Row
• Shkreli Says His New Co. Doesn't Violate FTC's Pharma Ban
• Patheon Claims Arranta Figures Lied In Chancery Trial
• Red And Blue State AGs Join Legal Fight Over Abortion Pill
• Opioid Judge Targets 'Unfortunate' Gaps In Pharmacy Deals
• EpiPen Rebates Help Middlemen, Not Patients, Justices Told
• HIV Drug Buyers Rip Gilead's Dismissal Bid As 'Nothing New'
• Quest Diagnostics Accused Of 'Abusive' Billing Practices
• What DOJ's 2022 Recovery Stats Say About FCA Enforcement
• Latham-Led Biotech, Renewable Energy Firms Price 2 IPOs
• Law360 Seeks Members For Its 2023 Editorial Boards
• Pillsbury Adds Perkins Coie Venture Capital Atty In Calif.
• Robins Kaplan Adds Gov't Relations Atty From Jackson Lewis
• 3 Firms Guide Pair Of Blank-Check IPOs Totaling $160M
• Atty Conflict Discussions In Idaho Murder Case And Beyond
• Conn. Docs Not Liable For Pot User's Lies About PTSD
• UK Litigation Roundup: Here's What You Missed In London
• HSF Hires 5-Atty Team From Simmons & Simmons In Italy
• Teva Slams Lilly's 'Scorched-Earth' Tactics In Migraine Battle
• HHS Memos, 5 Senate Bills Target Drug Prices And Tactics
• Syngenta, Corteva Pesticide Antitrust Cases Centralized In NC
• Fed. Circ. Affirms Partial Ax Of Guardant Genetic Test Patent
• Courts Must Apply Correct Causal Standard In Kickback Cases
• South Korea Fines German Auto Cos. $33M Over Emissions
• Bayer Unit Asks 3rd Circ. To Keep Roundup Suit Federal
• THC False Ad Plaintiffs Oppose Dismissal Conditions
• Chicago Says Dobbs Decision Forecloses Vax Challenge
• How A Dusty Law Review Article Entered The Post-Roe Debate
• Higher Ed Can't Recycle Cannabis Policies For Psychedelics
• Why The Original 'Rocket Docket' Will Likely Resume Its Pace
• Orrick Lures Ex-Hughes Hubbard Arbitration Pro To NY Office
• 1st Circ. Unsure Polling Gaffes Merit Automatic New Trial
• Globus Medical, NuVasive Combine In $3.1B All-Stock Merger
• Sens. Call Out Health Cos. For Sharing Data With Advertisers
• Merck Seeks Dismissal Of NC Gardasil Vax Claims
• Illustrator Tries Again To Keep $3.6M Infringement Award
• Fed. Circ. Mulls Amgen-Sandoz Psoriasis Drug Dispute
• Fla. Judge Orders Halt To Infringing Canine Implant Sales
• Centene Cuts $215M False Claims Act Deal With Calif. AG
• Consumers And Insurers Get Class Cert. In Valsartan MDL
• Eli Lilly Hit With New Age Bias Suit Over Millennial Push
• Chancery Nixes Early Trial On Masimo Board Control Defense
• NotPetya Triggers War Exclusion, Insurers Tell NJ Panel
• Medical Equipment Suppliers Convicted Of $3.8M Fraud
• Medtronic Unit Hit With $106.5M Heart Valve Patent Trial Loss
• Vitamin Shoppe Hyped Weak Muscle Powder, 1st Circ. Told
• An Applicant's Guide To USPTO's Examiner Incentive System
• Viela Bio Shareholders Sue AstraZeneca In Del. After $3B Sale
• Investors In Conn. Ultrasonics Co. Sue For Share Appraisal
• CBD Co. Copied Trademark, Vitamin Co. Says
• White House Seeks More US-Made Materials For Infrastructure
• Texas Says HHS Can't Make Pharmacies Sell Abortion Pills
• DOJ Reveals One Of FCA's Smallest Hauls In Many Years
• Philip Morris Patent Fight Has Fed. Circ. About To Combust
• Zantac Plaintiffs Must File Separate Complaints, Judge Says
• The Pill Club To Pay $15M To Settle Medi-Cal Fraud Claims
• Drug Execs Testify About DEA Compliance In Ga. Opioid Trial
• Instacart Co-Founder Hit With TRO In Trade Secrets Fight
• FTC Shows Privacy Heft With Groundbreaking GoodRx Action
• Sullivan & Worcester Launches Boston Permitting Practice
• Ionis Shareholders Come Together In Del. Pay Suit Deal
• Sorrento Can't Nix $175M Arbitration Loss To LA Times Owner
• EU To Consider Ban On Toxic 'Forever Chemicals'
• Kraft Says Class Needs To Back Up Capri Sun PFAS Suit
• Medicare Developments Ahead For Remote Health Monitoring
• Jury Finds Capital Inventory's Ex-Execs Stole Trade Secrets
• Bankruptcies Aren't The Real Problem In Mass Tort System
• The Discipline George Santos Would Face If He Were A Lawyer
• Pharma Co. Sued In Del. For Docs On Undisclosed IP Value
• DC Court Nixes Challenge To Canadian Medicine Import Rule
• Shift In Health Care Antitrust Prosecutions Is Likely
• Masimo Rolls Back Board Control Shields Targeted In Del. Suit
• Ex-NC Sen. Burr Joins DLA Piper As Principal Policy Adviser
• 'No Surprises' Medical Billing Rule Is Still Illegal, Judge Rules
• Pfizer Must Produce Exchanges With FBI In Data Swiping Suit
• Ohio Abortion Clinics Tell Justices To Leave Block On Law
• Cos. Sued Over Recalled Eyedrops Linked To Outbreak
• Eli Lilly Worker's Proposed Class Suit Over 401(k) Fees Nixed
• Ga. Family Reveals Generational Opioid Addiction At Trial
• PTAB Again Axes Cochlear Implant IP After Vidal Remand
• How FTC's Broadened Health Ad Guidance Affects Marketers
• Labcorp Inks $19M False Claims Act Deal In 10-Year-Old Case
• PhaseBio Suitor Gets $2M Breakup Fee Without Ch. 11 Auction
• Catching Up With Delaware's Chancery Court
• Seyfarth Accused Of Ushering Bad Deal On Companies' Sale
• Ohio Neurologist Given 2½ Years For Drug Kickback Scheme
• Barnes & Thornburg Grows In NJ, Pa. With 5 New Attys
• Ex-Rep. Ron Kind Joins Arnold & Porter Public Policy Group
• Opioids Ravaged Ga. Family, Jury Told In Distributor Case
• Sanofi Urges Justices To Deny Amgen's 'Monopoly' Attempt
• GoodRx Holdings Hit With Class Action Over Data Sharing
• 10th Circ. Erases CSA Convictions After High Court Ruling
• Philip Morris Says Baltimore Litter Rules Usurp Federal Law
• Cooley, Latham Steer Biotech Startup's Upsized $161M IPO
• Australia Legalizes Prescribing Of Psilocybin And MDMA
• 'Green Shoots' Start To Emerge From A Bruised IPO Market
• DC Circ. Won't Revisit Revival Of Pharma Terror-Funding Case
• Masimo Urges Chancery To Uphold Founder's Takeover Shield
• Pending FDA Cosmetics Review Allows Class Action Defense
• Health Hires: Manatt Phelps, vTv Therapeutics
• A Litigation Move That Could Conserve Discovery Resources
• Issues To Watch In Fla.'s Telehealth Genetic Counseling Bills
• 20 AGs Warn CVS, Walgreens Against Mailing Abortion Pills
• ITC Clears Cannabis Cos. In Vaping IP Investigation
• Harvard Ducks Some Vizgen Counterclaims In Patent Row
• IP Forecast: Fed. Circ. To Eye Cooley's Conduct In CBD Row
• 11th Circ. Affirms Injured Pelvic Mesh Patient's Trial Win
• Ex-USPTO Chiefs Say Patent System 'Overhaul' Not Needed
• Questions Surround FDA's Orphan Drug Exclusivity Approach
• Litigators Should Approach AI Tools With Caution
• Pharmacy Tech Co. Gets Partial Costs In Defense Deal Dispute
• Goodwin Adds 4 More Troutman Attys In Philadelphia And NY
• Lamictal Drug Buyers Lose Another Class Certification Bid
• O'Melveny Adds Finnegan Practice Group Leader In DC
• Latham Adds Gunderson Dettmer Emerging Cos. Atty In Calif.
• Regeneron Says DOJ Cried Fraud 'Despite Knowing The Truth'
• Psychedelics Bill Roundup: Wash. State Mulls Psilocybin
• Canadian, Israeli Cannabis Cos. Terminate $35M Merger Deal
• Fla. Mental Health Provider Is Sued Over Patient Data Breach
• Eisai Settles Recalled Diet Drug Cancer Claims
• Biotech Co. Seeks $3.62M From Shipper Over Frozen Medicine
• FDA Outlines Views Of Clinical Trials Without Placebo Groups
• Hospital's Bid For Pandemic Bonuses Nixed By Old Policy
• Magistrate Judge Advises Cutting Illumina's Gene IP Theft Suit
• Christopher Warren Joins Buchanan Ingersoll As Counsel
• Integra GC Dinged By NJ Ethics Board Over Pa. License Lapse
• Vanda Sues FDA Over Approval Of Teva Generic Sleep Drug
• Duane Morris Adds 2 Ex-Oblon McClelland IP Partners In DC
• Insys Founder Asks To Leave Prison After 2 Heart Attacks
• Boston Scientific Hit With $42M Stent Patent Verdict
• Kirkland-Led Patient Square Clinches Record $3.9B Fund
• FTC Targets GoodRx In 1st Action Under Health Breach Rule
• Wilson Sonsini Expands In DC With Longtime SEC Atty